Medtronic and Merit Medical Systems enter into agreement to offer new, FDA-cleared ViaVerteâ"¢ system, a basivertebral nerve ablation treatment for chronic vertebrogenic lower-back pain Accessibility StatementSkip Navigation Exclusive agreement expands Medtronic's comprehensive pain interventions portfolio, increases treatment options for patients living with chronic pain GALWAY, Ireland, March 24, 2026 /PRNewswire/ -- Medtronic plc, a global leader in healthcare technology, today announced that it has ente ...

一众跨国医械集团领导人正齐聚北京！ 3月22日至23日，2026年中国发展高层论坛在北京隆重召开，吸引了全球工商界、国际组织及世界500强企业的100多位外方代表出席。其中，12家跨国医 疗企业高管受邀参会，涵盖美敦力公司全球董事长兼首席执行官杰夫·马萨（Geoff Martha）、西门子医疗全球首席执行官孟天齐（Bernd Montag）、雅培 公司董事长兼首席执行官罗赋德（Robert Ford）、直观医疗首席执行官罗岱威（Dave J.Rosa）、欧加隆代理首席执行官约瑟夫·莫里斯（Joseph Morrissey）、罗氏集团董事会主席施万（Severin Schwan）、赛默飞世尔科技董事长兼首席执行官葛士柏（Marc Casper）等知名医疗器械领域龙头企业。 器械之家整理了会议期间，医械行业领导人的会议行程和重要讲话内容，其中密集释放了加码在华投资、深化本土合作的明确信号，彰显了中国市场在全 球医械产业格局中的核心地位。 01 高层会见搭桥梁 论坛开幕前夕，跨国医械企业高管已开启密集对接交流，为深化在华合作奠定基础。3月21日下午，商务部部长王文涛在北京集体会见美国药品研究与制 造企业协会总裁兼首 ...

Medtronic OmniaSecureâ"¢ defibrillation lead is the first lead of its kind to receive FDA approval for conduction system pacing Accessibility StatementSkip Navigation Built for high reliability, world's only lumenless defibrillation lead approved for placement in the left bundle branch area GALWAY, Ireland, March 23, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for an expanded indication for the OmniaSecur ...

Core Viewpoint - Medtronic's recent earnings report shows mixed results, with a slight decline in adjusted earnings per share and a notable increase in revenues, but the stock has underperformed the S&P 500, raising questions about its future performance [1][2]. Financial Performance - Medtronic reported Q3 fiscal 2026 adjusted earnings per share of $1.36, a decrease of 2.2% year-over-year, but it exceeded the Zacks Consensus Estimate by 2.07% [3]. - The company's worldwide revenues for the quarter reached $9.02 billion, reflecting an 8.7% year-over-year increase on a reported basis and 6% organically, surpassing the Zacks Consensus Estimate by 1.35% [4]. Segmental Analysis - Revenues from the Cardiovascular segment increased 10.6% organically to $3.46 billion, with Cardiac Rhythm & Heart Failure sales rising 17% year-over-year to $1.86 billion [5][6]. - The Medical Surgical segment reported worldwide sales of $2.17 billion, up 2.7% year-over-year organically, with Acute Care & Monitoring revenues increasing by 7% to $519 million [7]. - Neuroscience revenues totaled $2.56 billion, up 2.5% year-over-year organically, while revenues in the Diabetes group rose 8.3% organically to $796 million [8]. Margin Performance - The gross margin contracted by 265 basis points to 63.8%, attributed to a 17.3% increase in the cost of products sold [9]. - Research and development expenses rose by 7% year-over-year to $722 million, and selling, general, and administrative expenses increased by 8.8% to $2.96 billion [9]. Future Outlook - For fiscal 2026, Medtronic projects organic revenue growth of 5.5%, with the Zacks Consensus Estimate for worldwide revenues at $36.04 billion [10]. - The expected full-year adjusted earnings per share range is $5.62-$5.66, with the Zacks Consensus Estimate at $5.64 [11]. Estimate Trends - Recent estimates for Medtronic have trended downward, indicating a potential shift in investor sentiment [12][14]. - The stock currently holds a Zacks Rank 3 (Hold), suggesting an expectation of an in-line return in the coming months [14]. Industry Comparison - Medtronic operates within the Zacks Medical - Products industry, where competitor Phibro Animal Health has seen a 2.3% gain over the past month, reporting revenues of $373.9 million, a year-over-year increase of 20.9% [15]. - Phibro's expected earnings for the current quarter are $0.72 per share, reflecting a 14.3% increase from the previous year, with a Zacks Rank 1 (Strong Buy) [16].

Core Insights - Medtronic plc (NYSE:MDT) has agreed to acquire Scientia Vascular for approximately $550 million, with additional payments contingent on future milestones [2][3]. Group 1: Acquisition Details - Scientia Vascular is a private company based in Utah, specializing in guidewires and catheters designed to facilitate navigation through complex brain blood vessels [3]. - The acquisition aims to enhance Medtronic's position in stroke and neurovascular procedures, where quick and precise access to blocked or damaged vessels is crucial [3]. - The deal is expected to close in the first half of FY27, pending regulatory approvals, and is anticipated to be minimally dilutive to Medtronic's adjusted EPS in FY27, becoming accretive thereafter [4]. Group 2: Strategic Importance - Linnea Burman, senior vice president of Medtronic's Neurovascular business, emphasized that the acquisition will accelerate innovation in neurovascular care and provide a comprehensive suite of products [4]. - The integration of Scientia's technology with Medtronic's existing neurovascular products is expected to improve procedural efficiency and patient outcomes, addressing the needs of the 12 million individuals affected by stroke globally each year [4].

Core Viewpoint - Artificial intelligence (AI) is viewed as a long-term investment opportunity, with concerns about a potential bubble in AI-focused stocks [1] Group 1: Eli Lilly - Eli Lilly is experiencing significant growth, particularly in the weight-loss drug market, leading to rapidly increasing revenue and earnings [6] - The company's dividend program has seen a 239.2% increase over the past decade, although its forward yield is 0.6%, lower than the S&P 500 average of 1.2% [7] - Eli Lilly is leveraging AI to enhance drug development processes, having built a powerful computer in collaboration with Nvidia, which could lead to faster drug launches and improved profit margins [7][8] - The company's success is not solely dependent on AI advancements, as it is already performing well independently of broader AI industry trends [8] Group 2: Medtronic - Medtronic is a leading medical device manufacturer with a diverse product portfolio that ensures consistent revenue and earnings [9] - The company is gradually integrating AI into its operations, improving product performance, such as in the LINQ II cardiac monitor, which has benefited from AI algorithms to reduce false alerts [9]

Looking for more investing ideas like this one? Get them exclusively at The Dividend Kings. Learn more >>Those who have followed my work over the last seven-plus years on Seeking Alpha know that my investing philosophy mostly centers around dividend growth and value.Hi, my name is Kody. Aside from my articles here on Seeking Alpha, I am also a regular contributor to Sure Dividend, The Dividend Kings, and iREIT+Hoya Capital. I have been investing since September 2017 (age 20) and interested in dividend inves ...

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.Merck & Co Inc (NYSE:MRK)Medtronic PLC (NYSE:MDT)UnitedHealth Group Inc (NYSE:UNH)Photo via Shutterstock ...

Core Viewpoint - Medtronic has announced a definitive agreement to acquire Scientia Vascular for $550 million, aiming to enhance its product offerings in the neurovascular intervention market [2][4]. Group 1: Acquisition Details - The acquisition is characterized as a tuck-in acquisition, focusing on strengthening Medtronic's existing neurovascular product line with Scientia's devices, which include neurovascular guidewires and catheters [2][4]. - The deal is subject to customary closing conditions and includes undisclosed performance-based milestones [2]. - Medtronic plans to integrate Scientia's products into its neurovascular product system to improve the stroke treatment process [6]. Group 2: Market Context - The global stroke intervention market is becoming increasingly competitive, prompting large medical device companies to acquire firms to fill gaps in their product lines [3][14]. - The demand for neurovascular interventions is growing, with more countries establishing stroke center networks, leading to an increase in the volume of neurovascular procedures [15][22]. - The acquisition trend among major device companies indicates a shift towards building comprehensive product portfolios that cover the entire treatment process from access to therapy [21]. Group 3: Implications for the Industry - The acquisition reflects a broader trend in the neurovascular industry where companies are focusing on complete surgical solution systems rather than individual devices [20]. - In China, the neurovascular market has become one of the most active segments, with several companies expanding into access devices, indicating a competitive landscape [18][21]. - The ongoing construction of stroke centers is expected to sustain rapid growth in the neurovascular market, potentially accelerating industry consolidation [22].

Core Viewpoint - Medtronic plc (NYSE:MDT) is recognized as one of the 13 undervalued dividend aristocrats worth buying now [1]. Group 1: Company Overview - Medtronic develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally [2]. Group 2: Dividend Information - Medtronic declared a quarterly dividend of $0.71 per share on March 5, payable on April 17 to shareholders of record at the close of business on March 27, 2026 [3]. - The company has increased its annual dividend for the last 48 years, maintaining its status as a dividend aristocrat, with an annual dividend yield of 3.18% [3]. Group 3: Financial Performance - Medtronic reported better-than-expected results for Q3 2026, beating estimates in both earnings and revenue, with a 6% year-over-year organic revenue growth, the highest in ten quarters [4]. - The company aims for approximately 5.5% organic revenue growth for FY 2026 and maintains its adjusted EPS guidance in the range of $5.62 to $5.66 for the year [5].